HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Keymed Biosciences (2162.HK) - The Potential for Doubling Valuation and the Corresponding Risks

Beijing Airdoc Technology (2251.HK) - Not Optimistic About Turning Loss into Profit

Pre-IPO MicroPort NeuroTech - The Industry, the Business and the Concern

Pre-IPO ClouDr Group - The Logical Business Model Can Support Future Growth

JD Health (6618.HK) 2021 Results - The Logic and the Outlook

Pre IPO Shukun Technology - Obvious Strength in Technology/Products but Commercialization Is the Key

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Beijing Yuanxin Technology Group Co Ltd / Equity Capital Markets

Beijing Yuanxin Technology Group Co Ltd (1865453D CH)

<ul>
<li>Based on the business analysis, <a href="https://www.smartkarma.com/entities/beijing-yuanxin-technology-group-co-ltd" target="_blank" data-smartkarma-citation="entities:34685:1" rel="noopener">Beijing Yuanxin Technology Group Co Ltd (1865453D CH)</a> is more of a traditional offline chain drugstores than a healthcare technology company.</li>
<li>Yuanxin has been suffering from loss for years. With a gross margin of lower than 10%, it's going to be tough to turn a profit, leading to concerns on survival. </li>
<li>Due to the fierce competition in each of its businesses, homogeneous business model, weak financial position, lack of high moat, policy risks, etc., we are conservative about the Company’s outlook.</li>
</ul>


Based on the business analysis, Beijing Yuanxin Technology Group Co Ltd (1865453D CH) is more of a traditional offline chain drugstores than a healthcare technology company.
Yuanxin has been suffering from loss for years. With a gross margin of lower than 10%, it's going to be tough to turn a profit, leading to concerns on survival. 
Due to the fierce competition in each of its businesses, homogeneous business model, weak financial position, lack of high moat, policy risks, etc., we are conservative about the Company’s outlook.


Winning Health Technology Group Co., Ltd. A (300253 CH)

Winning Health Technology Group Co., Ltd. A

Ping An Healthcare and Technology (1833 HK)

Yixintang Pharmaceutical Group (002727 CH)

DaShenLin Pharmaceutical Group (603233 CH)

Medbanks Network Technology (1690522D CH)

Pre-IPO Beijing Yuanxin Technology Group - Conservative About the Outlook